La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cyclopharm Dividende

Dividende contrôle des critères 0/6

Informations clés

Rendement du dividende

Ratio de distribution

Rendement moyen de l'industrie	1.6%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	AU$0.010
Résultat par action	-AU$0.042
Prévisions de rendement du dividende à 3 ans	0.7%

Mises à jour récentes des dividendes

Recent updates

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Oct 28

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Mar 02

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Oct 22

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Jun 29

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Apr 27

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Mar 01

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Feb 07

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

Jan 02

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Dec 06

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de CYC ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de CYC ont augmenté.

Rendement des dividendes par rapport au marché

Cyclopharm Rendement des dividendes par rapport au marché

Comment le rendement du dividende de CYC se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (CYC)	0%
25% du marché (AU)	2.6%
25% du marché (AU)	6.1%
Moyenne du secteur (Medical Equipment)	1.6%
Prévisions des analystes dans 3 ans (CYC)	0.7%

Dividende notable: Impossible d'évaluer le rendement des dividendes de CYC par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Bénéfice distribué aux actionnaires

Couverture des revenus: CYC ne verse pas de dividende notable pour le marché Australian.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car CYC n'a signalé aucun versement.

Cyclopharm Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023

Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023

Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022

Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022

Recent updates

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Market cap size

Consensus revenue estimates fall by 14%

Cyclopharm Limited, Annual General Meeting, May 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director

Consensus EPS estimates fall by 11%

CEO, MD exercised options to buy AU$402k worth of stock.

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: AU$0.032 loss per share (vs AU$0.028 loss in 1H 2022)

Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023

Consensus estimates of losses per share improve by 13%

Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Consensus EPS estimates fall by 153%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023

Less than half of directors are independent

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Less than half of directors are independent

Cyclopharm Limited Appoints Gregory King as A Non-Executive Director

Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director

First half 2022 earnings released: AU$0.028 loss per share (vs AU$0.045 loss in 1H 2021)

Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022

Consensus revenue estimates increase by 10%

Cyclopharm Limited Announces Independent Multicentre Study Highlights the Benefits of Technegas in Diagnosing Pulmonary Embolism in Growing Covid-19 Patient Population

Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Cyclopharm Limited Announces Technegas Used in Diagnosing Long COVID

Full year 2021 earnings: Revenues exceed analyst expectations

Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Consensus revenue estimates increase by 14%

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022

Cyclopharm Limited Provides Earnings Guidance for the Full Year 2021

Less than half of directors are independent

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.045 loss per share (vs AU$0.074 loss in 1H 2020)

Cyclopharm Limited Provides Unaudited Revenue Guidance for the First Half of 2021

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Consensus revenue estimates fall to AU$16.5m

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Cyclopharm Limited provides Confirmation of Technegas USFDA Timetable

Analysts increase revenue estimates to AU$18.6m

Cyclopharm Limited, Annual General Meeting, May 04, 2021

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Cyclopharm Limited Provides Update on USFDA Approval to Distribute Technegas in the USA in 2021

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

New 90-day high: AU$3.10

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

New 90-day high: AU$2.63

Cyclopharm Limited Announces A New Research Collaboration with Mcmasters University

New 90-day high - AU$1.59

First half earnings released

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés